Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma

Cancer Research

Volumn 70, Issue 16, 2010, Pages 6467-6476

  Albesiano, Emilia ^a   Davis, Meghan ^b   See, Alfred P ^b   Han, James E ^b   Lim, Michael ^b   Pardoll, Drew M ^a   Kim, Young ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; STAT3 PROTEIN; CYTOKINE; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; LEUKOCYTE MIGRATION; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; LEUKOCYTE; NEUTROPHIL CHEMOTAXIS; TUMOR CELL LINE; TUMOR ESCAPE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; DENDRITIC CELLS; HEAD AND NECK NEOPLASMS; HUMANS; LEUKOCYTES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; TUMOR ESCAPE;

EID: 77955760903     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4058     Document Type: Article

References (39)

1. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
2. Darnell JE. Validating Stat3 in cancer therapy. NatMed2005;11:595-6.
3. Nagpal JK, Mishra R, Das BR. Activation of stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 2002;94:2393-400. (Pubitemid 34457120)
4. Sen M, Tosca PJ, Zwayer C, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 2008;63:983-95. Epub 2008 Sep 3.
5. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13:1235-42. (Pubitemid 44750735)
6. Kong LY, Wei J, Sharma AK, et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanomathrough inhibition of regulatory T cells. Cancer Immunol Immunother 2009;58:1023-32.
7. Homsi J, Cubitt C, Daud A. The src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 2007;11:91-100. (Pubitemid 46099755)
8. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
9. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314. (Pubitemid 28448572)
10. Darnell JE, Jr. STATs and gene regulation. Science 1997;277:1630-5.
11. Hackenmiller R, Kim J, Feldman RA, Simon MC. Abnormal stat activation, hematopoietic homeostasis, and innate immunity in c-fes-/- mice. Immunity 2000;13:397-407.
12. Harris TJ, Grosso JF, Yen HR, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007;179:4313-7.
13. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10:39-49. (Pubitemid 29077382)
14. Welte T, Zhang SS, Wang T, et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 2003;100:1879-84. (Pubitemid 36254542)
15. Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173:3844-54. (Pubitemid 39280747)
16. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.
17. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51. (Pubitemid 46020826)
18. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
19. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells. Nat Med 2004;10:48-54. (Pubitemid 38524698)
20. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21. (Pubitemid 41752912)
21. Cheng F, Wang HW, Cuenca A, et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003;19:425-36. (Pubitemid 37153418)
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-δδ C(T)) method. Methods 2001;25:402-8.
23. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the src oncoprotein. Science 1995;269:81-3.
24. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: Implications for cancer therapy. Oncogene 2005;24:970-9.
25. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552-60. (Pubitemid 43119350)
26. Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993;177:1809-14. (Pubitemid 23146150)
27. Van Damme J, Decock B, Lenaerts JP, et al. Identification by sequence analysis of chemotactic factors for monocytes produced by normal and transformed cells stimulated with virus, double-stranded RNA or cytokine. Eur J Immunol 1989;19:2367-73. (Pubitemid 20024766)
28. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
29. Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999;18:4657-68. (Pubitemid 29415520)
30. Narvaiza I, Mazzolini G, Barajas M, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 2000;164:3112-22. (Pubitemid 30148972)
31. Enderlin M, Kleinmann EV, Struyf S, et al. TNF-α and the IFN-γ-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 2009;16:149-60.
32. Paillard F. Cytokine and chemokine: a stimulating couple. Hum Gene Ther 1999;10:695-6.
33. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66. (Pubitemid 28544331)
34. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008;113:750-7.
35. Squarize C, Castilho R, Sriuranpong V, et al. Molecular cross-Talk between NF-kB and STAT3 signaling pathways in head and neck squamous carcinoma. Neoplasia 2009;8:733-46.
36. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114-23.
37. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-κ;B activity in tumors. Cancer Cell 2009;15:283-93.
38. Pan Q, Gorin MA, Teknos TN. Pharmacotherapy of head and neck squamous cell carcinoma. Expert Opin Pharmacother 2009;10:2291-302.
39. Gupta S, El-Rayes BF. Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics 2008;2:707-15.